# Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)

> **NCT01558739** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 48 (actual)

## Conditions studied

- Primary Myelofibrosis (PMF)
- Post Polycythaemia Myelofibrosis (PPV MF)
- Post Essential Thrombocythaemia Myelofibrosis (PET-MF)

## Interventions

- **DRUG:** INC424

## Key facts

- **NCT ID:** NCT01558739
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2015-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01558739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01558739, "Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT01558739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*